SCHEMBL528874

SCHEMBL528874

NN(C=O)C1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 12/20 0.54
ADH1C P00326 9/20 0.52
ADH4 P08319 3/20 0.50
ADH1B P00325 3/20 0.46
ADH7 P40394 1/20 0.34
FDPS P14324 1/20 0.32
PHGDH O43175 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18570188 1.00 ADH1A (0.54) ADH1AADH1CADH4ADH1BADH7
SCHEMBL3956369 0.97
SCHEMBL27719489 0.95
SCHEMBL27845046 0.91 ADH1A (0.46) ADH1AADH1CADH4ADH1BADH7
SCHEMBL2453051 0.86
SCHEMBL28057896 0.75 ADH1A (0.33) ADH1AADH1CADH4
SCHEMBL27121722 0.74 ADH1A (0.37) ADH1AADH1CADH4ADH1BPHGDH
SCHEMBL28005038 0.73 APLNR (0.38) ADH1AADH1CADH4ADH1B
SCHEMBL28040278 0.73 APLNR (0.38) ADH1AADH1CADH4ADH1B
SCHEMBL14855293 0.72 ADH1A (0.94) ADH1AADH1CADH4ADH1BADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036545-A Recycled polypropylene toughening modifier and application thereof 太原科技大学 2026-05-15 CN claimed
CN-110105355-A A kind of preparation method of 1,2,3- triazole-[1,5-a] and quinolines 烟台大学 2019-08-09 CN claimed
EP-2597955-B1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE INC (JP) 2016-01-20 EP claimed
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US claimed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US claimed
US-8013153-B2 Substituted pyrimidine kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2011-09-06 US claimed
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 US claimed
WO-2007109783-A2 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-09-27 WO claimed
CN-122036545-A Recycled polypropylene toughening modifier and application thereof 太原科技大学 2026-05-15 CN disclosed
CN-115552235-A Method for evaluating purity of drug contained in complex and method for producing complex 东丽株式会社 2022-12-30 CN disclosed
CN-113562855-A Environment-friendly efficient boiler water regulator for drum boiler 浙江砉润科技有限公司 2021-10-29 CN disclosed
CN-110105355-A A kind of preparation method of 1,2,3- triazole-[1,5-a] and quinolines 烟台大学 2019-08-09 CN disclosed
CN-109642024-A Active targeting type polymeric derivative, the composition comprising the polymeric derivative and their purposes 日本化药株式会社 2019-04-16 CN disclosed
EP-2597955-B1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE INC (JP) 2016-01-20 EP disclosed
US-8013153-B2 Substituted pyrimidine kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2011-09-06 US disclosed
US-20110058244-A1 ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2011-03-10 US disclosed
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 US disclosed
WO-2007109783-A2 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-09-27 WO disclosed
EP-0947510-B1 Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts BASF AG (DE) 2002-02-13 EP disclosed
EP-0947510-A1 Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts BASF AKTIENGESELLSCHAFT (DE) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS DTYMK, TK1, DCK ADH1A 3002/4885ADH1C 3456/4885ADH4 2984/4885
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME MELK, NADK, NEK1 ADH1A 3757/4885ADH1C 4443/4885ADH4 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.